TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding Psoriasis Clinical Study With Adalimumab
Brief Summary: The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab retreatment in participants who had therapeutic response to adalimumab and were then withdrawn from adalimumab treatment.


Options:
A: Arm Label: AIN457 150 mg - Fixed Interval (FI); Type: EXPERIMENTAL; Interventions: Drug: AIN457 150 mg, Drug: Placebo | Arm Label: AIN457 150 mg - Start of relapse (SoR); Type: EXPERIMENTAL; Interventions: Drug: AIN457 150 mg, Drug: Placebo | Arm Label: AIN457 300 mg - Fixed Interval (FI); Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Arm Label: AIN457 300 mg - Start of Relapse (SoR); Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg, Drug: Placebo | Arm Label: AIN457 300 mg - Open Label (OL); Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Intervention Type: DRUG; Name: AIN457 150 mg; Assigned to Arm(s): AIN457 150 mg - Fixed Interval (FI), AIN457 150 mg - Start of relapse (SoR) | Intervention Type: DRUG; Name: AIN457 300 mg; Assigned to Arm(s): AIN457 300 mg - Fixed Interval (FI), AIN457 300 mg - Open Label (OL), AIN457 300 mg - Start of Relapse (SoR) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): AIN457 150 mg - Fixed Interval (FI), AIN457 150 mg - Start of relapse (SoR), AIN457 300 mg - Start of Relapse (SoR)
B: Arm Label: Apremilast 30 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast 30 mg BID | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Apremilast 30 mg BID, Placebo
C: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: ActiveTreatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): ActiveTreatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
D: Arm Label: Adalimumab; Type: OTHER; Interventions: Drug: adalimumab | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): Adalimumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding Psoriasis Clinical Study With Adalimumab
Brief Summary: The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab retreatment in participants who had therapeutic response to adalimumab and were then withdrawn from adalimumab treatment.


Options:
A: Arm Label: LAS41008; Type: EXPERIMENTAL; Interventions: Drug: LAS41008 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LASW1835; Type: ACTIVE_COMPARATOR; Interventions: Drug: LASW1835 | Intervention Type: DRUG; Name: LAS41008; Assigned to Arm(s): LAS41008 | Intervention Type: DRUG; Name: LASW1835; Assigned to Arm(s): LASW1835 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
C: Arm Label: Adalimumab; Type: OTHER; Interventions: Drug: adalimumab | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): Adalimumab
D: Arm Label: Apremilast 30 mg plus placebo injection; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Drug: Placebo injection | Arm Label: Etanercept 50 mg plus placebo tablet; Type: EXPERIMENTAL; Interventions: Drug: Etanercept, Drug: Placebo tablet | Arm Label: Oral placebo tablets plus SC placebo injections; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet, Drug: Placebo injection | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast 30 mg plus placebo injection | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept 50 mg plus placebo tablet | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Etanercept 50 mg plus placebo tablet, Oral placebo tablets plus SC placebo injections | Intervention Type: DRUG; Name: Placebo injection; Assigned to Arm(s): Apremilast 30 mg plus placebo injection, Oral placebo tablets plus SC placebo injections

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding Psoriasis Clinical Study With Adalimumab
Brief Summary: The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab retreatment in participants who had therapeutic response to adalimumab and were then withdrawn from adalimumab treatment.


Options:
A: Arm Label: UCB4940 8 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 40 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 160 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 480 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 640 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: UCB4940; Assigned to Arm(s): UCB4940 160 mg, UCB4940 40 mg, UCB4940 480 mg, UCB4940 640 mg, UCB4940 8 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: etanercept | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C
C: Arm Label: AIN457 300 mg; Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab 45/90 mg, Drug: placebo secukinumab | Intervention Type: DRUG; Name: AIN457 300 mg; Assigned to Arm(s): AIN457 300 mg | Intervention Type: DRUG; Name: ustekinumab 45/90 mg; Assigned to Arm(s): Ustekinumab | Intervention Type: DRUG; Name: placebo secukinumab; Assigned to Arm(s): Ustekinumab
D: Arm Label: Adalimumab; Type: OTHER; Interventions: Drug: adalimumab | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): Adalimumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding Psoriasis Clinical Study With Adalimumab
Brief Summary: The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab retreatment in participants who had therapeutic response to adalimumab and were then withdrawn from adalimumab treatment.


Options:
A: Arm Label: 80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: 80 mg Ixekizumab Dosing Regimen 2 (Q4W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: 80 mg Ixekizumab Dosing Regimen 3 (Q12W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3; Assigned to Arm(s): 80 mg Ixekizumab Dosing Regimen 2 (Q4W), 80 mg Ixekizumab Dosing Regimen 3 (Q12W), 80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Single-Arm, open-label extension trial; Type: OTHER; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Single-Arm, open-label extension trial
C: Arm Label: Secukinumab; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Ustekinumab
D: Arm Label: Adalimumab; Type: OTHER; Interventions: Drug: adalimumab | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): Adalimumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center Continuation Trial for Patients Completing Study M02-518 and M02-570 of the Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients With Moderate to Severely Active Psoriatic Arthritis
Brief Summary: The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in treatment of moderate to severely active psoriatic arthritis


Options:
A: Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Adalimumab 40 mg sc every other week; Assigned to Arm(s): N/A
C: Intervention Type: BIOLOGICAL; Name: Human anti-TNF monoclonal antibody/adalimumab; Assigned to Arm(s): N/A
D: Arm Label: Group 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Biological: Golimumab 50 mg | Arm Label: Group 2: Golimumab 50 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 50 mg | Arm Label: Group 3: Golimumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1: Placebo | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): Group 1: Placebo, Group 2: Golimumab 50 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): Group 3: Golimumab 100 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi Center, Open Label Study of the Human Anti TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Brief Summary: To evaluate the long-term maintenance of response, safety and tolerability of repeated administration of adalimumab in subjects with Crohn's disease who participated in and successfully completed Protocol M02-404 or Protocol M04-691.


Options:
A: Arm Label: DB Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo eow; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: OL Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): DB Adalimumab 40 mg eow, OL Adalimumab 40 mg eow | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo eow
B: Arm Label: Adalimumab 160 mg/80 mg; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Adalimumab 80 mg/40 mg; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 160 mg/80 mg | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 80 mg/40 mg | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): N/A
D: Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label Long-Term Study to Evaluate the Safety of Depakote Extended Release Tablets in the Treatment of Mania Associated With Bipolar Disorder in Children and Adolescents
Brief Summary: To determine if long-term treatment, up to 6 months, with Depakote ER is safe and effective in the treatment of bipolar I disorder in children and adolescents.


Options:
A: Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: risperidone | Arm Label: Divalproex sodium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Divalproex Sodium | Intervention Type: DRUG; Name: Divalproex Sodium; Assigned to Arm(s): Divalproex sodium | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): Risperidone
B: Intervention Type: DRUG; Name: Divalproex Sodium Extended-Release Tablets; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Divalproex Sodium (Depakote ER); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: divalproex sodium; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis
Brief Summary: The purpose of the study is to assess the safety and clinical efficacy of adalimumab in subjects with active ankylosing spondylitis


Options:
A: Arm Label: Back pain / peripheral arthritis; Type: N/A; Interventions: N/A
B: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab (D2E7) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab (D2E7); Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab (D2E7) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab (D2E7); Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: All subjects; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): All subjects

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis
Brief Summary: The purpose of the study is to assess the safety and clinical efficacy of adalimumab in subjects with active ankylosing spondylitis


Options:
A: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab (D2E7) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab (D2E7); Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Back pain / peripheral arthritis; Type: N/A; Interventions: N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Etanercept (Enbrel) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Etanercept (Enbrel); Assigned to Arm(s): A | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): B
D: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab (D2E7) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab (D2E7); Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Healthy Eating, Aerobic and Resistance Training in Youth (HEARTY) Trial
Brief Summary: The purpose of this study is to evaluate the effects of resistance training, aerobic training, and combined aerobic and resistance training on percent body fat, measured using Magnetic Resonance Imaging (MRI), in sedentary post-pubertal overweight or obese youth aged 14-18 years.


Options:
A: Arm Label: Multifaceted intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Multifaceted intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multifaceted intervention; Assigned to Arm(s): Multifaceted intervention
B: Arm Label: CBT for depression and healthy lifestyle plus exercise; Type: EXPERIMENTAL; Interventions: Behavioral: CBT for depression and healthy lifestyle plus exercise | Arm Label: CBT for depression; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CBT for depression | Intervention Type: BEHAVIORAL; Name: CBT for depression and healthy lifestyle plus exercise; Assigned to Arm(s): CBT for depression and healthy lifestyle plus exercise | Intervention Type: BEHAVIORAL; Name: CBT for depression; Assigned to Arm(s): CBT for depression
C: Intervention Type: BEHAVIORAL; Name: weight management program; Assigned to Arm(s): N/A
D: Arm Label: Diet and Aerobic Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: aerobic and resistance exercise | Arm Label: Diet and Resistane Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: aerobic and resistance exercise | Arm Label: Diet and Combined Aerobic and Resistance Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: aerobic and resistance exercise | Arm Label: Diet-only control group; Type: OTHER; Interventions: Behavioral: aerobic and resistance exercise | Intervention Type: BEHAVIORAL; Name: aerobic and resistance exercise; Assigned to Arm(s): Diet and Aerobic Exercise, Diet and Combined Aerobic and Resistance Exercise, Diet and Resistane Exercise, Diet-only control group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Synthetic Conjugated Estrogens, B (Enjuvia) 0.3 mg Tablets for the Treatment of Vulvovaginal Atrophy in Healthy Postmenopausal Women
Brief Summary: This is a two-arm, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy of Enjuvia 0.3 mg tablets for the treatment of moderate to severe symptoms of vulvovaginal atrophy in postmenopausal women with or without a hysterectomy and/or oophorectomy.


Options:
A: Intervention Type: DRUG; Name: estradiol, 10 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estradiol, 25 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
B: Arm Label: Testosterone undecanoate; Type: EXPERIMENTAL; Interventions: Drug: Testosterone undecanoate | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Testosterone undecanoate; Assigned to Arm(s): Testosterone undecanoate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Synthetic Conjugated estrogens, B | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Synthetic Conjugated estrogens, B; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Treatment with transdermal 17β-estradiol; Type: EXPERIMENTAL; Interventions: Drug: 17β-estradiol | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: 17β-estradiol | Intervention Type: DRUG; Name: 17β-estradiol; Assigned to Arm(s): Control, Treatment with transdermal 17β-estradiol

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder
Brief Summary: This is a placebo-controlled, double-blind study to evaluate the safety and efficacy of two doses of DR-3001 in women with overactive bladder who have symptoms of predominant or pure urge incontinence, urinary urgency and elevated urinary frequency


Options:
A: Intervention Type: DRUG; Name: Tolterodine ER; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Arm Label: YM178 group; Type: EXPERIMENTAL; Interventions: Drug: YM178 | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: tolterodine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: tolterodine | Intervention Type: DRUG; Name: YM178; Assigned to Arm(s): YM178 group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group | Intervention Type: DRUG; Name: tolterodine; Assigned to Arm(s): tolterodine group
C: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching Placebo | Intervention Type: DRUG; Name: Fesoterodine; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): Control
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: DR-3001a | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: DR-3001b | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: DR-3001a; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: DR-3001b; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3

Answer: D